Abbott (NYSE:ABT) plans to restrict the use of its Absorb bioresorbable stent in Europe after a clinical study found a higher risk of serious adverse events.
In a March 31 letter to physicians (posted online April 5 by a prominent cardiologist from Atlanta), Abbott said it would restrict use of the Absorb and Absorb GT1 devices to clinical registry studies as of May 31.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott to restrict Absorb bioresorbable stent in Europe appeared first on MassDevice.
from MassDevice http://ift.tt/2p8ZZux
Cap comentari:
Publica un comentari a l'entrada